ramipril and Weight-Loss

ramipril has been researched along with Weight-Loss* in 4 studies

Reviews

1 review(s) available for ramipril and Weight-Loss

ArticleYear
Studies examining risk reduction in subjects with multiple metabolic and cardiovascular risk factors.
    Current hypertension reports, 2000, Volume: 2, Issue:2

    Topics: Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 1; Exercise; Humans; Hypertension; Lisinopril; Male; Obesity; Ramipril; Risk Factors; Weight Loss

2000

Other Studies

3 other study(ies) available for ramipril and Weight-Loss

ArticleYear
[A 93-year-old patient with hypertensive crises and renal failure due to bilateral renal artery stenosis].
    MMW Fortschritte der Medizin, 2015, Nov-05, Volume: 157, Issue:19

    Topics: Aged, 80 and over; Angioplasty; Carbazoles; Carvedilol; Combined Modality Therapy; Diagnosis, Differential; Drug Therapy, Combination; Female; Humans; Hypertension; Hypertension, Renovascular; Life Style; Propanolamines; Ramipril; Renal Artery Obstruction; Stents; Weight Loss

2015
Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes.
    Current atherosclerosis reports, 2008, Volume: 10, Issue:2

    Diabetes mellitus (DM) is a worldwide epidemic. Its prevalence is rapidly increasing in both developing and developed countries. Coronary heart disease (CHD) is highly prevalent and is the major cause of morbidity and mortality in patients with diabetes. Individuals with prediabetes states, with or without known CHD, should undergo lifestyle modifications aimed at preventing DM. In patients with CHD and DM, routine use of aspirin and an angiotensin-converting enzyme inhibitor, along with strict glycemic, blood pressure, and lipid control, is strongly recommended. Intense insulin therapy may be needed for glycemic control, and high-dose statin therapy may be needed for lipid control. For blood pressure control, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are considered first-line therapy. Noncompliance with medications and/or lifestyle measures and underprescription of evidence-based therapies remain important unsolved problems.

    Topics: Antihypertensive Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Diabetic Angiopathies; Humans; Hyperglycemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Life Style; Myocardial Infarction; Obesity; Pioglitazone; Piperidines; Platelet Aggregation Inhibitors; Prediabetic State; Pyrazoles; Ramipril; Rimonabant; Risk Assessment; Thiazolidinediones; Triglycerides; Weight Loss

2008
[Corner points of antihypertensive therapy in prediabetic state. Success with a combination].
    MMW Fortschritte der Medizin, 2003, Jul-10, Volume: 145, Issue:27-28

    Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Exercise; Humans; Hypertension; Patient Compliance; Prediabetic State; Ramipril; Risk Factors; Weight Loss

2003